Fulcrum Therapeutics is a biotechnology business based in the US. Fulcrum Therapeutics shares (FULC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.36 – an increase of 9.28% over the previous week. Fulcrum Therapeutics employs 45 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Fulcrum Therapeutics stock
How to buy Fulcrum Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – FULC. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Fulcrum Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Fulcrum Therapeutics stock price (NASDAQ: FULC)
Use our graph to track the performance of FULC stocks over time.Fulcrum Therapeutics shares at a glance
| Latest market close | $8.36 |
|---|---|
| 52-week range | $2.32 - $10.11 |
| 50-day moving average | $8.38 |
| 200-day moving average | $6.05 |
| Wall St. target price | $13.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.14 |
Is it a good time to buy Fulcrum Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Fulcrum Therapeutics price performance over time
Historical closes compared with the close of $7.67 from 2025-11-10
| 1 week (2025-11-06) | 0.26% |
|---|---|
| 1 month (2025-10-13) | -12.34% |
| 3 months (2025-08-13) | 11.97% |
| 6 months (2025-05-13) | 32.47% |
| 1 year (2024-11-13) | 115.45% |
|---|---|
| 2 years (2023-11-13) | 121.04% |
| 3 years (2022-11-11) | 7.42% |
| 5 years (2020-11-13) | 12.65 |
Fulcrum Therapeutics financials
| Gross profit TTM | $-52,400,000 |
|---|---|
| Return on assets TTM | -20.63% |
| Return on equity TTM | -31.21% |
| Profit margin | 0% |
| Book value | $3.67 |
| Market Capitalization | $441.1 million |
TTM: trailing 12 months
Fulcrum Therapeutics share dividends
We're not expecting Fulcrum Therapeutics to pay a dividend over the next 12 months.
Fulcrum Therapeutics share price volatility
Over the last 12 months, Fulcrum Therapeutics's shares have ranged in value from as little as $2.315 up to $10.11. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fulcrum Therapeutics's is 3.185. This would suggest that Fulcrum Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Fulcrum Therapeutics overview
Fulcrum Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc.
Frequently asked questions
nullWhat percentage of Fulcrum Therapeutics is owned by insiders or institutions?
Currently 1.529% of Fulcrum Therapeutics shares are held by insiders and 101.477% by institutions. How many people work for Fulcrum Therapeutics?
Latest data suggests 45 work at Fulcrum Therapeutics. When does the fiscal year end for Fulcrum Therapeutics?
Fulcrum Therapeutics's fiscal year ends in December. Where is Fulcrum Therapeutics based?
Fulcrum Therapeutics's address is: 26 Landsdowne Street, Cambridge, MA, United States, 02139 What is Fulcrum Therapeutics's ISIN number?
Fulcrum Therapeutics's international securities identification number is: US3596161097 What is Fulcrum Therapeutics's CUSIP number?
Fulcrum Therapeutics's Committee on Uniform Securities Identification Procedures number is: 359616109
Ask a question
More guides on Finder
-
How to Buy Stocks Without a Broker
Here are several ways to invest in stocks directly, without a brokerage account, plus the pros and cons of not using a stock broker.
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2025
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
Best Stocks for Beginners With Little Money in 2025: Start With $1!
These are the stocks to buy when you don’t have much to spend.
-
8 Best Day Trading Apps of 2025
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Best Brokerage Account Bonuses for November 2025
Explore the best bonuses for opening a new brokerage account.
-
11 Best Trading Apps for Beginners
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
-
5 Best International Brokerage Accounts
Interactive Brokers is the best overall international brokerage account on our list, followed by Moomoo, Fidelity, Charles Schwab and TradeStation.
-
Top 9 Low-Cost Stock Brokers for 2025: Save On Every Trade
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
10 Top Oil Stocks to Buy in 2025
We’ve rounded up stats on some of the most popular oil stocks, along with information on how they compare and how to invest.